Compare
Ensysce Biosciences, Inc. vs ProPhase Labs, Inc. vs China Pharma Holdings, Inc. vs Korro Bio, Inc.
| Latest fiscal year | Ensysce Biosciences, Inc. ENSC | ProPhase Labs, Inc. PRPH | China Pharma Holdings, Inc. CPHI | Korro Bio, Inc. KRRO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.07M | $4.34M | $4.14M | $6.39M |
| Revenue growth (YoY) | -2.8% | -35.8% | -8.5% | +181.5% |
| Gross margin | n/a | 31.9% | -3.2% | n/a |
| Operating margin | -202.1% | -415.4% | -78.2% | n/m |
| Net margin | -200.8% | -339.3% | -76.9% | n/m |
| Net income | -$10.18M | -$14.74M | -$3.19M | -$117.26M |
| EPS (Diluted) | -$3.98 | -$1.74 | -$0.74 | -$12.48 |
| Operating cash flow | -$7.81M | -$8.34M | $148.3K | -$78.56M |
| Free cash flow | -$7.93M | -$8.34M | $88.9K | -$79.08M |
| Cash & equivalents | $4.31M | $90.0K | $345.1K | $21.82M |
| Total assets | $7.45M | $59.87M | $31.00M | $113.51M |
| Total liabilities | $4.57M | $56.36M | $8.26M | $62.07M |
| Shareholders' equity | $3.21M | $3.51M | $22.74M | $51.44M |
| Return on year-end equity | -316.6% | -420.3% | -14.0% | -228.0% |
| Shares outstanding | 4.57M | 8.97M | 15.52M | 9.42M |
Revenue, most recent five fiscal years
| Fiscal year | Ensysce Biosciences, Inc. | ProPhase Labs, Inc. | China Pharma Holdings, Inc. | Korro Bio, Inc. |
|---|---|---|---|---|
| Latest | $5.07M Ended 2025-12-31 | $4.34M Ended 2025-12-31 | $4.14M Ended 2025-12-31 | $6.39M Ended 2025-12-31 |
| 1 year earlier | $5.21M Ended 2024-12-31 | $6.77M Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $2.27M Ended 2024-12-31 |
| 2 years earlier | $2.23M Ended 2023-12-31 | $34.98M Ended 2023-12-31 | $7.01M Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $2.52M Ended 2022-12-31 | $122.65M Ended 2022-12-31 | $8.10M Ended 2022-12-31 | n/a |
| 4 years earlier | $3.53M Ended 2021-12-31 | $79.04M Ended 2021-12-31 | $9.64M Ended 2021-12-31 | n/a |